- Home
- AMGN vs PGR Comparison
AMGN vs PGR Comparison
Compare AMGN & PGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- PGR
- Stock Information
- Founded
- AMGN 1980
- PGR 1937
- Country
- AMGN United States
- PGR United States
- Employees
- AMGN N/A
- PGR N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- PGR Property-Casualty Insurers
- Sector
- AMGN Health Care
- PGR Finance
- Exchange
- AMGN Nasdaq
- PGR Nasdaq
- Market Cap
- AMGN 156.2B
- PGR 161.3B
- IPO Year
- AMGN N/A
- PGR N/A
- Fundamental
- Price
- AMGN $288.18
- PGR $284.90
- Analyst Decision
- AMGN Buy
- PGR Buy
- Analyst Count
- AMGN 21
- PGR 16
- Target Price
- AMGN $323.62
- PGR $287.31
- AVG Volume (30 Days)
- AMGN 3.2M
- PGR 2.7M
- Earning Date
- AMGN 05-01-2025
- PGR 07-15-2025
- Dividend Yield
- AMGN 3.30%
- PGR 0.14%
- EPS Growth
- AMGN 56.16
- PGR 51.82
- EPS
- AMGN 10.94
- PGR 14.83
- Revenue
- AMGN $34,126,000,000.00
- PGR $78,508,000,000.00
- Revenue This Year
- AMGN $7.62
- PGR $15.54
- Revenue Next Year
- AMGN $1.88
- PGR $10.97
- P/E Ratio
- AMGN $26.34
- PGR $19.21
- Revenue Growth
- AMGN 15.56
- PGR 20.74
- 52 Week Low
- AMGN $253.30
- PGR $201.34
- 52 Week High
- AMGN $346.85
- PGR $292.99
- Technical
- Relative Strength Index (RSI)
- AMGN 58.41
- PGR 56.81
- Support Level
- AMGN $269.10
- PGR $273.42
- Resistance Level
- AMGN $276.90
- PGR $280.44
- Average True Range (ATR)
- AMGN 5.90
- PGR 5.64
- MACD
- AMGN 2.48
- PGR -0.54
- Stochastic Oscillator
- AMGN 97.70
- PGR 73.21
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About PGR Progressive Corporation (The)
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 24 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.